SCHEMBL7212909

SCHEMBL7212909

COc1ccc2c(c1)C(=C=CC=O)c1cccnc1CO2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
ALOX12 P18054 1/20 0.45
RAB9A P51151 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP19A1 P11511 2/20 0.39
MAOB P27338 4/20 0.37
MAOA P21397 1/20 0.35
PPIB P23284 1/20 0.34
APP P05067 2/20 0.34
TBXA2R P21731 2/20 0.33
CTSD P07339 1/20 0.33
BACE1 P56817 1/20 0.33
MAPK14 Q16539 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL654789 0.79 ALDH1A1 (0.66) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL7212914 0.79 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL7206375 0.78 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL7206378 0.78 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL12121841 0.78 MAPT (0.50) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL654200 0.77 MAPT (0.49) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL7210858 0.72 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL10288244 0.72 CCR1 (0.42) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL7210855 0.72 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL4060672 0.68 ALDH1A1 (0.66) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613905-B1 Treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation MILLENNIUM PHARMACEUTICALS, INC. 2003-09-02 US disclosed